Current Studies

Clinical Studies

Trailblazer
Alzheimer’s

AVP
Alzheimer’s

AZT-001
Alzheimer’s

Embark
Alzheimer’s

BAN2401-201 OLE
Alzheimer’s

Clarity
Alzheimer’s

Graduate
Alzheimer’s

Mirror
Uncontrolled Gout

Alithios
Multiple Sclerosis

Exchange
Multiple Sclerosis

Novo Select
Cardiac

Sk Life Science
17/21 Seizures

PrecMed
Parkinson’s

PrecMed
Alzheimer’s

PrecMed
Multiple Sclerosis

Traumatic
Brain Injury

Trailblazer Alzheimer's Study

The Trailblazer Alzheimer’s Study involves people who have normal memory, thinking, mood and behavior patterns. Participants are randomly assigned to one of two groups. They receive either the investigational drug or a placebo. Those who receive placebo may have the option to receive the investigational drug at a later time.

You may be able to take part in this study if you:

AVP Alzheimer’s Study

The ASPECT Study will look at an investigational medication for people with Alzheimer’s Disease. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug for agitation associated with Alzheimer’s Dementia.

The ASPECT Study might be right for you if you:

AZT-001 Alzheimer’s Study

This clinical research trial is enrolling men and women who may have evidence of early stage Alzheimer’s disease. The clinical trial is evaluating whether a combined treatment slows down early stage Alzheimer’s disease.

Qualified participants must:

Embark Alzheimer’s Study

Subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies.

Qualified participants must:

BAN2401-201OLE Alzheimer’s Study

This medical study is for people who are experiencing increasing problems with their memory that may be early symptoms of Alzheimer’s disease. This study will evaluate the effectiveness of an investigational product (study drug). You must have been enrolled in the double-blind study.

Qualified participants must:

Clarity Alzheimer’s Study

18-Month study with an open-label extension phase to confirm safety and efficacy of an investigational drug in subjects with early Alzheimer’s Disease.

Qualified participants must:

Graduate Alzheimer’s Study

Study With an Open-Label Extension Phase to Confirm Safety and Efficacy in subjects with early (prodromal to mild) Alzheimer’s.

Qualified participants must:

MIRROR Gout Study

A study testing efficacy and safety of two drugs to increase response rates in patients with Uncontrolled Gout.

Qualified participants must:

Alithios Multiple Sclerosis Study

An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of an investigational drug in subjects with relapsing multiple sclerosis.

Qualified participants must:

Exchange Multiple Sclerosis Study

An open label study exploring safety and tolerability of conversion to Oral Siponimod in patients with relapsing multiple sclerosis.

Qualified participants must:

Select Cardiac Study

Effects of Semaglutide on cardiovascular outcomes in people with overweight or obesity.

Qualified participants must:

SK Life Science 17/21 Seizure Study

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension.

Qualified participants must:

PrecMed Parkinson’s Study

The purpose of this medical study is to collect biological samples from subjects with Parkinson’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Parkinson’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Parkinson’s disease. Your samples will be kept indefinitely by the sponsor.

PrecMed Alzheimer’s Study

The purpose of this medical study is to collect biological samples from subjects with Alzheimer’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Alzheimer’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Alzheimer’s disease. Your samples will be kept indefinitely by the sponsor.

PrecMed Multiple Sclerosis Study

The purpose of this medical study is to collect biological samples from subjects with Multiple Sclerosis. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Multiple Sclerosis or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Multiple Sclerosis. Your samples will be kept indefinitely by the sponsor.

Traumatic Brain Injury

The purpose of this medical study is to evaluate an investigational drug to see if it could potentially help behavioral changes resulting from a Traumatic Brain Injury (TBI). Many people are diagnosed with a TBI every year, including a significant number of veterans. This injury could lead to a number of behavioral changes, including outbursts and acts of aggression. This could be behavioral changes associated with the traumatic brain injury from at least 6 months ago. This clinical study is seeking these participants to research this investigational drug. Participants must have a study partner who interacts with them regularly and can attend all in-clinic study visits. There are no FDA-approved medications specifically for behavioral symptoms resulting from a TBI.